Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 3 5Phase 1 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Leiomyoma 8Prostatic Neoplasms 5Menorrhagia 5Myofibroma 2Prostate Adenocarcinoma 1Endometriosis 1

Interventions

Prednisone 53Radiotherapy 52Docetaxel 51Leuprolide 48Goserelin 47bicalutamide 45enzalutamide 28acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27Androgen Antagonists 27Flutamide 24Triptorelin Pamoate 22apalutamide 18Gonadotropin-Releasing Hormone 18Abiraterone Acetate 17Radiation 15abiraterone 14Zoledronic Acid 14Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 12Prednisolone 11luprolide acetate gel depot 10darolutamide 9Radiosurgery 9cabazitaxel 8Standard of Care 8Specimen Handling 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Estramustine 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Neoplasms × relugolix × Clear all
NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Emory University

Phase 3 Recruiting
72 enrolled
Genitourinary

Prostatic Neoplasms

NCT05605964 2025-08-17

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Sumitomo Pharma America, Inc.

Phase 3 Completed
387 enrolled
Genitourinary

Prostatic Neoplasms

NCT03085095 2022-01-18

HERO

Myovant Sciences GmbH

Phase 3 Completed
1,134 enrolled 38 charts 1 FDA
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡